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Death is never an easy topic for clinicians to discuss with their patients, even when it can be foreseen in the course
of illness or during the progression of a disease.  For liver disease, where the patient population is typically younger
and the trajectory of the disease more uncertain than other potentially terminal diseases, care at the end of life
poses additional and particular challenges.  
The End of Life Care Strategy was published by the Department of Health in 2008 and there have been general
improvements in delivery of care since then.  For many clinicians involved in the treatment of people with liver
disease, however, who are immersed in detail of acute care and ‘rescuing’ patients from complications, considering
end of life care issues, care planning and having difficult conversations about death can become obscured.
Liver doctors have developed several predictive models of death and seem to recognise very well the signs leading
up to the end phase of life yet surprisingly few have developed programmes to help those patients or their families
either to appreciate this or to navigate the realities and hurdles of their final months of life.  
For these reasons we have sought to bring together evidence and opinion on the issue here in one place, which we
hope will help to improve the way we address this issue in the NHS. We hope that this document, focusing on end
of life care for patients with liver disease, will help clinicians, educators, commissioners and patients to discuss this
important issue, and to work towards improvements in service provision and outcomes.  
I would like to offer my sincere thanks to the many people, including patient groups, hepatologists,
gastroenterologists and palliative care physicians and nurses, who have contributed to this document (who we have
listed in Appendix C). If their enthusiasm and creativity can be replicated at a local level, using this document as a
useful resource to drive conversations and action to improve services, we will have achieved our aims.
Foreword
Professor Martin Lombard
National Clinical Director for Liver Disease
Department of Health
05
Executive Summary
EX
EC
U
TI
V
E 
SU
M
M
A
RY
Liver disease is a significant public health issue, and in 2010 it represented the fifth biggest cause of death
after cancer, circulatory disease, respiratory disease and dementia1. Of particular concern is that whilst the
mortality for cancer, circulatory and respiratory disease is falling, deaths due to liver disease are relentlessly
rising. It is therefore a significant issue for health care providers across all settings and also for commissioners
of health care. 
The fluctuating course of liver disease makes identification and management of the end of life period
challenging. Patients may benefit from both active medical management and palliative and supportive care.
Integration of these processes allows active treatment of medical crises whilst preparing the patients, those
close to them and the clinical team for the possibility of death. This will require a change in culture amongst
some healthcare professionals and the ability to share acknowledgement that recovery is uncertain.
The Department of Health’s End of Life Care Strategy described an end of life care pathway in six steps, to
help provide excellent end of life care. This includes:
1. Discussions as end of life approaches – some prognostic indicators or clinical triggers for liver 
disease have been identified.
2. Assessment, care planning and review – there is a need to identify healthcare professionals who, 
with appropriate training, could discuss prognosis and future care preferences with patients who 
have advanced liver disease.
3. Co-ordination of care – an identified healthcare professional needs to coordinate care to minimise 
duplication and ensure information is shared promptly between healthcare providers. 
4. High quality care in different settings – each patient will need identified contacts for palliative care 
advice and liver advice both in and out of hours.
5. Care in the last days of life – patients with advanced liver disease can have complex medical needs 
and may require frequent medical attention as death approaches, highlighting the need for care 
planning and review of preferred place of death as illness progresses.
6. Care after death – bereaved relatives of liver disease patients can have complex psycho-social needs 
both before and after the patient’s death needing support.
The pathway also includes carer support, social care, spiritual care and access to end of life information as
overarching considerations.
This document takes the end of life care pathway as described in the End of Life Care Strategy and considers
how it can be applied for patients with advanced liver disease.
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This document aims to set out a strategic approach to improve end of life care for those living with advanced liver
disease.
Patient Groups 
• This document should help patient groups to have a role in discussion about the provision of end of life care 
for people with advanced liver disease.  There are particular issues and problems in liver disease which they will
be familiar with and can help at a local level to develop improvements in care for those with advanced liver 
disease.
Providers of Healthcare
• The increase in deaths from liver disease may encourage providers to explore this area of healthcare for 
patients with liver disease as part of ongoing development in this area. 
• Providers may wish to assess if their workforce has the skills needed to deliver excellent end of life care in 
terms of communication skills and knowledge. 
• Providers may also need to identify who in their organisation is best placed to take responsibility for each step 
in the end of life care pathway. 
• Providers may also like to think about who can provide clinical leadership to bring about the changes in culture
required.
Commissioners
• Commissioners may find it useful to benchmark their current situation against this document and use the 
output of that to inform commissioning intentions. 
• Commissioners may like to think about how to commission access to liver advice and palliative care advice 24/7.
How this document might be used
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What is end of life care?
A working definition of end of life care is care that helps all those with advanced, progressive, incurable illness
to live as well as possible until they die. It enables the supportive and palliative care needs of both patient and
family to be identified and met throughout the last phase of life and into bereavement. It includes
management of pain and other symptoms and provision of psychological, social, spiritual and practical
support2.
End of life care and active treatment can carry on simultaneously. End of life care should not be restricted to a
patient’s last few weeks and days when death is felt to be imminent and inevitable. When a patient has a
condition or symptoms that may persist up to the point of death then active treatment and palliative strategies
can be integrated, allowing the patient, carers and professionals to proceed with active therapy while
anticipating and preparing for the possibility of death. This ‘plan B’ approach avoids the nihilistic or defeatist
connotations of introducing palliative strategies and leaves the door open for patients to anticipate, enquire
about and plan for future deteriorations in their health. An acknowledgement that in a given condition or
situation ‘recovery is uncertain’ can allow patients and professionals to engage in shared decision making
about how treatment should proceed now and in the event of potential or anticipated future deterioration.
What do we know about end of life care for people with liver disease?
The National End of Life Care Intelligence Network published a report this year into deaths from liver disease
and the implications for end of life care in England3. This report shows there has been a 25% increase in liver
disease deaths between 2001 (9,231 people) and 2009 (11,575 people). This is in contrast to other major
causes of death, which have been declining. 
Whilst only 2% of the population as a whole die from liver disease, 90% of these people are under 70.
Indeed, more than 1 in 10 of deaths of people in their 40s is from liver disease. When measured as ‘years of
life lost’, liver disease is therefore much more prominent.
The report highlights that 60% of deaths from liver disease occurred amongst men and 40% amongst
women. The most common diagnosis is alcohol-related liver disease, accounting for well over a third (37%) of
all liver disease deaths. Furthermore, 22% of liver deaths are from primary liver cancer, the majority of which
will have alcohol-related liver disease as their underlying cause. However the prevalence of deaths from
alcohol-related liver disease varies greatly between males (41% of liver disease deaths) and females (30% of
liver disease deaths). Alcohol-related liver disease is also more common in the most deprived areas (44% of
liver disease deaths) than the least deprived areas (28% of liver disease deaths).
The complex needs of many patients who die from liver disease mean that over 70% die in hospital, compared
to 55% of total deaths in 2009. 
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The number of people affected also varies in different parts of the country making it a greater issue and challenge
in some areas. The age standardised mortality rate (2001-09) was highest in: 
• North West (24.0 per 100,000, of which 11.4 were from alcohol-related liver disease) 
• North East (21.9 per 100,000, of which 10.1 were from alcohol-related liver disease) 
• London (20.2 per 100,000, of which 6.5 were from alcohol-related liver disease)
Data from Nottinghamshire suggest that people who die from alcohol related liver disease have on average seven
hospital contacts in the preceding five years, suggesting that there is often opportunity to identify advanced liver
disease and offer opportunities for care planning4. 
The results of the Department of Health’s first survey of bereaved people (the ‘VOICES survey’)5, which asks people
who register a death about their relative’s experience of end of life care, were published earlier this year. It is
expected that this survey will be repeated regularly and will be a key data source for measuring the end of life care
indicator in the NHS Outcomes Framework. The first sample included 367 responses from carers of someone with
liver disease, and this number is expected to increase as the survey is repeated. Results from this first report
included:
• Where liver disease was mentioned, carers were less likely to rate the overall quality of care as outstanding 
compared with others, and were more likely to rate the overall quality of care as poor.
• Where liver disease was mentioned, carers were less likely to rate the quality of care by GPs as excellent 
compared with others, and were more likely to rate their care as poor. There were no significant differences in 
ratings for care of hospital staff.
• Where liver disease was mentioned, carers were more likely to rate the co-ordination of care as not working 
well together compared with others. For hospital services with community services, where liver disease was 
mentioned carers were less likely to rate the co-ordination as working together ‘to some extent’.
What national policy or guidance is there on end of life care?
End of Life Care Strategy
The End of Life Care Strategy was published in 2008 and sets out six key steps for an end of life care pathway, to
provide guidance to anyone providing health and social care to people nearing the end of life. The care pathway
aims to ensure that high quality, person-centred care is provided which is well planned, co-ordinated and monitored
while being responsive to the individual’s needs and wishes6. Such principles are obviously also applicable to those
dying from end stage liver disease. 
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Figure: The End of Life Care Pathway
The cross-cutting themes of carer support, patient and carer information, social care and spiritual, cultural and
psychological care are particularly relevant in liver disease where the need for such services is often
considerable but the provision is limited compared to other fields such as cancer care.
NHS Outcomes Framework
In the new NHS architecture, the NHS Outcomes Framework7 will be used to provide a national-level overview
of how well the NHS is performing, to act as an accountability mechanism between the Secretary of State and
the NHS Commissioning Board, and as a catalyst for quality improvement through the NHS. It is structured
around five domains, which set out the high-level national outcomes that the NHS should be aiming to
improve. 
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The NHS Outcomes Framework will measure improvements in end of life care in Domain Four.  This will be
measured through a survey of bereaved relatives (the ‘VOICES survey’).
NICE Quality Standard
In November 2011, the National Institute for Health and Clinical Excellence published a Quality Standard on end of
life care for adults8.  The Quality Standard contains 16 quality statements which cover all settings and services in
which care is provided by health and social care staff to all adults approaching the end of life. These standards are
broken down into structural, process and outcome measures, which could be measured and adapted for liver disease.   
The Secretary of State for Health and the NHS Commissioning Board will be under a duty to have regard to Quality
Standards in carrying out their functions, particularly their new statutory duty to improve service quality. The Board
will also use Quality Standards in developing the commissioning guidance that clinical commissioning groups will
have to follow.
Equalities
The Department of Health has published evidence that some groups in society have reduced access to, or
engagement with, end of life care services; some of these groups have a higher than average prevalence of liver
disease, so particular consideration should be given to equity of access to services and consideration of different
beliefs, values and behaviours. Guidance is available at:
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_086272.pdf 
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Why is end of life care for people with
liver disease particularly challenging?
For individuals…
• Deaths occur on average at a younger age than most other long term conditions
• Younger patients may not have pre-existing relationship with primary healthcare
• Indolent early phases of disease may result in patients presenting later in disease process
• Lifestyle and cultural barriers to accessing healthcare
• Perceived stigma resulting in decreased access to care
• Some patients may have on-going issues with addiction and mental health
• In contrast to cancer, lack of public awareness that liver disease is commonly fatal
For healthcare professionals…
• Complex and uncertain prognosis represents challenges to transition to end of life care
• Adoption of end of life care planning in parallel to active intervention in periods of uncertainty will 
require culture change in many hepatologists, gastroenterologists, intensivists and 
healthcare professionals
• Gastroenterology and hepatology training programmes do not currently teach end of life care
For healthcare organisations…
• Many hospitals may lack a specialist with an interest in liver disease
• Inconsistent access to out of hours specialist experience, both for liver and palliative care advice
• Number of people dying from liver disease is increasing which may put a strain on existing resources
12
When a person is dying of alcohol-related liver disease there are often additional needs for the family which might
require to be considered in the provision of end of life care. Living with a family member with alcohol related issues
affects family functioning and can contribute to problems with mental health or social functioning. As a
consequence there may be a need for specific counselling and additional input after the patient's death in order to
support the family in overcoming some of the long term affects of alcohol addiction and minimising their impact
on future family functioning.
Specialist clinicians who regularly encounter patients with advanced liver disease are often familiar with providing
high-quality management of symptoms (ascites, encephalopathy, itch, fatigue) when they become severe, and
have seen many patients present with such symptoms and respond temporarily to treatment several times before
death. Conversely we know from patient reports, that accessing expertise and high quality care for liver disease is
often a challenge for them.  This document aspires to set out an agenda for providing seamless integrated
high-quality care for patients with advanced liver disease, to manage symptoms and support early identification
and communication about advance care planning across healthcare settings from periods of active intervention to
care in the last days of life.
Trajectories of decline in liver disease
The concept of illness trajectory, the pattern in which a person’s general health and ability to function varies during
the course of an illness, can be useful in anticipating the final phase of life and the opportunity to benefit from
anticipatory care planning. It can also help explain why identifying the terminal phase of an illness can be difficult,
particularly in chronic organ failure conditions such as heart failure, COPD and advanced liver disease. In these
conditions, deteriorating health is not always a ‘one-way street’ and an episode of decline may reverse, either
spontaneously or with medical treatment, and a patient’s ability to function may return to a level at or near the
level it was at before the episode. Thus a rapid decline does not necessarily signal imminent, unavoidable death
and, unless the patient disagrees, it can be helpful to reassess progress after a period of (intensive or conservative)
management9. This fluctuating trajectory can be a challenge to manage across healthcare settings and for those
healthcare professionals with limited knowledge of liver disease.
Number of deaths in each trajectory, out of the average 20 deaths each
year per UK general practice list of 2000 patients
Cancer (n=5)
Organ failure (n=6)
Physical and cognitive frailty (n=7)
Other (n=2)
High
Low
Time
Death
Fu
nc
tio
n
Murray, S A et al. BMJ 2008; 336 958-959
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Patients with advanced liver disease can follow widely differing trajectories, and decisions about an individual
patient should be based on that patient’s individual progress, preferences and needs rather than a generalised
model of illness trajectory. Many patients with advanced liver disease experience repeated episodes of
deterioration (termed ‘decompensation’) when one or more symptoms (such as ascites, oedema,
encephalopathy, jaundice, bleeding) become more limiting and the patient’s ability to function declines.
Symptoms may fully or partially resolve either spontaneously or as a result of medical intervention with an
improvement in the patient’s ability to function. Some patients experience an episode of decompensation from
which they do not recover and death follows. Several factors may influence whether a particular episode
becomes a terminal decompensation, including: the patient’s physiological reserve (‘fitness’); the presence of
multiple symptoms; superadded complications such as infection or kidney failure; the timing, appropriateness
and vigour of medical intervention; and the patient’s views on and engagement with active treatment. It can
therefore be difficult for patients and professionals to judge the appropriate balance of palliative and active
interventions at the onset of an episode of decompensation. In these situations the shared acknowledgement
that ‘recovery is uncertain’ can facilitate integration of active and palliative management. Examples might
include:
1) Instituting vigorous organ support on the shared understanding that if health deteriorates despite the 
intervention it can be withdrawn, but alongside this active management, comfort and dignity are also 
maintained as a key focus of care. 
2) Setting ‘ceilings of active treatment’ to avoid interventions which patients and professionals agree 
would be futile or undesirable may be useful. Such decisions should be subject to repeated review and 
dialogue.
Transitions to supportive, palliative and end of life care
The integration of supportive and palliative care with active treatment is a new concept for many professionals
and yet so much of the care and treatment provided in managing liver disease is ‘palliative’ rather than
restorative.  Sometimes identification and management of the transition can be challenging. Research has
shown that there are no clear means of identifying the point at which end of life care will become necessary, so
to wait until the need is certain may result in missed opportunities for symptom control and advance care
planning10. The hepatology community, however, has for years been able to produce and use models that
predict poor outcomes but these still tend to be used to consider escalation of treatment (e.g. liver transplant)
rather than be used as a prompt for discussion of future care preferences.  
Recognising when it is appropriate to introduce elements of end of life care will vary with patient, clinician and
disease factors. A simple tool that can sometimes help to inform the process is the ‘surprise question’. This
prompts clinicians to ask themselves ‘Would I be surprised if this patient were to die within the next 12
months?’ or ‘…the next week?’ A pragmatic starting point is ‘Would I be surprised if this patient were to die in
the current circumstances?’ which can then lead on to the more time-dependent questions. This intuitive
approach to a complex question allows integration of specific diagnostic and prognostic indicators with
co-morbidity, functional, nutritional and social factors11. 
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Introduction
As detailed above, the end of life care pathway was described in the End of Life Care Strategy published by
the Department of Health in 2008.  In this chapter, each step of the care pathway is looked at individually and
its relevance to and application in the care of people with liver disease considered.
Step 1 Discussions as the end of life approaches
The ‘surprise question’ can help prompt discussions about end of life issues with patients whose liver disease is
becoming life-limiting. Experienced clinicians will often answer the question based on global impression (‘gut
feeling’) but specific triggers may help the process in advanced liver disease: http://www.spict.org.uk/ 
• Patients who have had one or more unplanned admissions with decompensation in the previous 12 
months have an increased probability of further and more frequent decompensation episodes and may 
benefit from increased supportive and palliative care.
• Patients who have been assessed for liver transplantation will have had an evaluation of their symptoms 
and risk of death in the following 12 months. This information can be used to guide supportive and 
palliative interventions independently of the decision to proceed to transplantation or not. Similarly 
patients who have been seen by hepatologists may have had a prognostic score calculated (eg Child 
Pugh, MELD, UKELD) which gives a cohort based probability of death and can prompt discussion of care 
preferences with patients.
• Decreasing performance status or ability to function.
• The presence of ascites, hydrothorax or encephalopathy that is unresponsive to treatment.
• Deteriorating renal function.
• Episodes of spontaneous bacterial peritonitis or severe infections.
• Recurrent variceal bleeding.
• Hepatocellular cancer that is metastatic or progressive despite locoregional therapy.
• Ongoing alcohol consumption in survivors of acute alcoholic hepatitis.
Once it has been identified that the patient may be reaching the end of their life it is essential that the primary
health care team are informed of this. It is important to clarify that the patient may receive active management
alongside palliative and supportive care. GPs have a palliative care register and reports suggest that patients on
these registers tend to have better co-ordinated palliative care in the community.
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Adopting the End of Life Care
Pathway for liver disease
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End of life care and liver transplantation
The majority of patients listed for liver transplantation have unresolved symptoms and 20% of patients on the
waiting list die before an organ becomes available. The wait for transplantation can generate additional social
and psychological difficulties for patients and those close to them. Being placed on the transplant waiting list
should prompt rather than preclude consideration of the need for supportive and palliative care. Transplant
co-ordinators and transplant social workers are well placed to co-ordinate this care12. Those patients who 
have been assessed and deemed unsuitable for transplant are a group with urgent need for palliative care
review; study has demonstrated their expected survival may be 2-3 months13. Proactive engagement with 
those declined a transplant who have advanced progressive disease should also be considered as by
definition this group of patients will be symptomatic and have a poor prognosis.
The content of end of life care discussions will vary with patients’ personalities, preferences, past experiences, social
circumstances and clinical condition. Some may not wish to engage in these discussions, others may find sufficient an
open acknowledgement that they are likely to die of liver disease and a reassurance that care will continue to be
guided by their needs and wishes, while others may accept the opportunity to ask about the future and engage in
advance care planning. Clinicians need to consolidate the skills needed to identify these needs in their patients and to
respond appropriately. Help in these difficult discussions can be found at:
http://www.endoflifecare.nhs.uk/search-resources/resources-search/publications/imported-publications/finding-the-words.aspx
http://www.endoflifecare.nhs.uk/education-and-training/communication-skills
Step 2 Assessment, care planning and review
Care planning for patients with advanced liver disease can be informed by the generic national guidance found at
http://www.endoflifecare.nhs.uk/care-pathway/step-2-assessment,-care-planning-and-review.aspx
Care planning embraces the care of people with and without capacity to make their own decisions. It involves a
process of assessment and person centred dialogue to establish the person’s needs, preferences and goals of care, and
making decisions about how to meet these in the context of available resources. It can be oriented towards meeting
immediate needs, as well as predicting future needs and making appropriate arrangements or contingency plans to
address these.
Should an individual with capacity wish to record choices about their care and treatment, in advance of losing capacity
they have several options. They could produce:
• An advance statement
• An advance decision to refuse treatment
• A Lasting Power of Attorney (for property and affairs, and/or health and welfare)
Where a person lacks capacity to decide, care planning must focus on determining their best interests (through
consultation with the person’s companions and key professional carers) and making decisions to protect these. Any
information about what the person’s views might have been about the issue at hand, and any relevant advance
statement (see below) that they made prior to their loss of capacity, should be taken into account when trying to work
out what is in their best interests. If a person who has lost capacity has a valid and applicable advance decision to
refuse treatment (ADRT) and / or has registered Lasting Powers of Attorney (LPA), these must be respected. Anything
done under the authority of the LPA must be in the person’s best interests.
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Any choices or advance decisions to refuse treatment recorded in advance of loss of capacity only become
relevant when a person loses the capacity to decide about those issues.
Where an individual has capacity to decide, then they must check and agree the content of any care planning
record.
The person concerned should be encouraged to regularly review any care planning documentation, to update
this as appropriate, and to ensure that revisions are shared with those they wish to involve in their care.
Important points relating to liver specific conditions include:
• Patients who are liable to become encephalopathic may have a fluctuating capacity so may wish to take 
part in advance care planning whilst they still have capacity. They may also have had previous experience 
of hospital treatment including intensive care management that they may be able to reflect on.  They may
wish to set out an advance statement, and advance decision to refuse treatment or appoint a lasting 
power of attorney for health and wellbeing who can make decisions for them when they lose capacity. 
Depending on their degree of encephalopathy some patients may retain capacity to make decisions 
about their care even when encephalopathic. Capacity is also specific to each individual decision to be 
made.
• Alcohol or drugs can temporarily affect a person’s capacity.
• Patients with established Wernicke-Korsakoff syndrome may lack capacity and so may need to have their 
capacity assessed and if found to be lost a decision regarding treatment must be made under the best 
interests section of the mental capacity act. 
If a person who lacks capacity has no close family or friends and has not recorded any choices about their care
and treatment or made an advance decision to refuse treatment in advance of losing capacity, then an
Independent Mental Capacity Advocate (IMCA) should be instructed and consulted regarding decision making
about serious medical treatment or about placement in hospital for longer than 28 days or a care home for
longer than eight weeks. 
The checklist in NHS North East guidelines (www.theclinicalnetwork.org) can be used as a framework for
professionals who are assisting patients with advanced liver disease in writing an emergency health care plan
(EHCP) or an advance decision to refuse treatment. An emergency health care plan allows people to set out
the treatment that they wish in an emergency. They are extensively used in paediatrics and in adults with
progressive life limiting disease to clarify goals of care and set ceilings of treatment. The list is not exhaustive
but highlights common liver-related problems which patients and care givers may wish to anticipate and
discuss with the most appropriate healthcare professional.
These discussions take time and need to be carried out at a pace which is comfortable for the patient. Whilst
some initial discussion regarding prognosis may need to take place during an inpatient admission, patients
may feel more able to make an informed decision about their future care once they have recovered from an
acute deterioration.
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Step 3 Co-ordination of Care
While many professionals may be involved in delivering medical, palliative, psychological and social care to a patient
with liver disease, it will help to identify a single professional to co-ordinate care. This will improve communication
with patients and between professionals, and minimise duplication or unintended interaction of investigations or
interventions. The professional best placed to co-ordinate care may change during the course of a person’s illness,
for instance it may be a hospital professional when hospital attendances are frequent with investigations,
interventions and treatment adjustments, then a GP when hospital attendances are fewer and community-based
interventions predominate, and a palliative care physician or nurse when there are challenging issues of symptom
management or hospice attendances. Frequent contact and information-sharing between professionals (for
instance, by prompt copies of clinical letters) will facilitate effective co-ordination and help maintain quality of care.
76% of the time is outside normal working hours so seamless information-sharing with out-of-hours providers is
essential. Patient-held information may help patients and carers to participate actively in the coordination of their
own care. Electronic palliative care co-ordination system (EPACCS) solutions being developed may help end of life
information to be shared electronically. National guidelines have been produced to help with sharing of information
electronically and can be accessed at:
http://www.endoflifecareforadults.nhs.uk/strategy/strategy/coordination-of-care/end-of-life-care-information-standard  
The co-ordinating professional will not necessarily be the best person to assist a patient with emergency health care
planning, advance decisions to refuse treatment and decisions about cardiopulmonary resuscitation (CPR). To make
these decisions, a patient may require information and assistance from more than one source. Gastroenterologists
and hepatologists may be best able to help a patient anticipate the healthcare emergencies that may arise in the
course of liver disease. Inclusion in the GP palliative care register means that care is likely to be better co-ordinated
in the community. However it must be made clear if the patient is for active management as well. Specialist
palliative care may also have a role to play in assisting with the most complex patients.
The co-ordinating professional should ensure that the documentation from any care planning is circulated to the
other professionals involved in care and lodged in relevant clinical records. See End of Life Care Co-ordination:
Record Keeping Guidance for more information –
http://www.endoflifecare.nhs.uk/assets/downloads/EoLC__Record_Keeping_Guidance_FINAL.pdf
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Step 4  High quality care in different settings
Providing high quality liver care includes providing high quality symptom management and supportive care for
patients whose symptoms are likely to persist or exacerbate up to the point of death. Patients with advanced
liver disease are often treated in a variety of settings (home, primary care, local hospital, regional liver centre)
and access to specialist palliative care and specialist liver medicine advice may be inconsistent. For each patient
there should be an identified contact for palliative care advice and an identified contact for liver advice so that
other professionals can maintain high quality care even when the clinical problem is not one with which they
are familiar. In an emergency, local arrangements should be in place for out-of-hours specialist palliative care
advice and out-of-hours emergency liver advice through regional liver centres, including the regional liver
centres providing advice on the relief of liver specific symptoms where necessary. Specialist palliative care
services include both hospital and community based services along with in-patient beds and day services in
hospices. Specialist palliative care services should be available to those patients with more complex physical
and psychosocial needs. The timing of a referral to specialist palliative care is dictated according to patient and
family ‘need’, not at a specific time point in their illness. Access may be appropriate much earlier on in the
disease trajectory and should not be reserved just for the last few weeks or days of life. Collaborative working
is essential in order to ensure high quality care is delivered.
Specific advice relating to achieving good end of life advice for people living in hostels or who are homeless
which may apply to some liver patients can be accessed at:
http://www.endoflifecare.nhs.uk/search-resources/resources-search/publications/ihm-eolc-rts-evaluation.aspx
Step 5 Care in the last days
Terminal care in advanced liver disease can require frequent medical attention if there are complex care needs
such as encephalopathy or haemorrhage. These needs may limit the number of patients whose death can be
supported at home or in nursing homes. Some patients and their families may feel more secure with the level
of medical attention available in hospital or hospice care. Ideally, patients who want to discuss their preferred
place of dying should have the opportunity to discuss their wishes and what this may mean in terms of
symptoms and treatment. These wishes can be recorded in an Emergency Health Care Plan (EHCP). Decisions
to decline specific treatments by a patient who wishes their decision to be followed in the event of their losing
capacity can be recorded in an Advance Decision to Refuse Treatment (ADRT).
Care in the last days of life can be guided by an end of life integrated care pathway14 such as the Liverpool
Care Pathway (LCP), to ensure high quality care is provided. The LCP has the advantage of being generic and
familiar to professionals in a range of clinical settings. The overall principles guiding practice apply but caution
is needed with some drug doses in end stage liver disease15. However, good symptom management is crucial
so regular clinical review is essential. Patients who have rapidly deteriorating kidney function may have more
effective palliation of symptoms if the renal prescribing guidelines for the LCP are used instead . More difficult
clinical situations may benefit from specialist palliative care input.
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Step 6 Care after death
Care after death includes timely certification of cause of death. Accurate inclusion of causes of liver disease,
particularly those due to alcohol, viral hepatitis and drug use, improves the accuracy of national mortality statistics
and informs the allocation of future health resources to fill unmet need. Families often read death certificates and
in some cases may have been unaware of elements of diagnosis. Such instances will require sensitive discussion.
Deaths due to alcohol can cause particular problems for those close to the patient with feelings of guilt and anger.
Opportunities for ongoing psychological and social support should be made available, for instance bereavement
counsellors may need additional training. Community alcohol services may want to think about their role in care
after death. Further information on care after death can be accessed at:
http://www.endoflifecare.nhs.uk/assets/downloads/Care_After_Death___guidance.pdf
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Education, training and continuous professional development
A recent report by the Royal College of Physicians (RCP) highlighted that delivery of good care at the end of
life cannot be left to specialists in palliative care but is an important part of the role of most physicians.
http://www.rcplondon.ac.uk/sites/default/files/eolc_clinicians_leaflet_web.pdf
The report contains the following important recommendations:
• Medical consultants should provide leadership in establishing opportunities for professional development 
in end of life care in their own settings, including agreeing how best to implement this as a 
department/directorate and across the trust. This will clearly apply to medical admitting teams, local 
hospital gastroenterology teams and regional liver centres.
• In order to influence their practice and ensure that patients have time to adjust, physicians must 
recognise that end of life care is not just care in the last few hours and days but that it marks the last 
phase of life, which may be many months or sometimes years.
• It also includes an important prompt tool for use on ward rounds and in out patients as well as a prompt 
tool to use at MDT meetings.
• It stresses the importance of all physicians including end of life care in their PDP and developing strong 
links with specialist palliative care teams.
• Secondary and tertiary care physicians must be informed of the fact that general practitioners have 
palliative care registers to help co-ordinate care for people in the community. 
• It would seem sensible for all units looking after people with liver disease to have a lead clinician for end 
of life care to champion the change in practice required.
• Local liver networks will be important for setting standards, developing regional procedures and guidance
and linking specialist advice and training.
• During admissions with decompensation the balance between ‘rescue’ and pragmatism can be difficult, 
particularly given the negative attitude that people with liver disease sometimes encounter from some 
healthcare professionals.  It is essential that liver specialists seize control of this space in order to best 
serve their patients’ needs.
The National End of Life Care Programme website also hosts a range of education and training tools, including
core competencies and principles for end of life care and an e-learning package. These can be found at:
http://www.endoflifecare.nhs.uk/education-training.aspx
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end of life care
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NHS North East liver network have developed a framework for supportive care in advanced liver disease
collaboratively between palliative care specialists and hepatologists. This aims to provide guidance for professionals
and can be accessed at: www.theclinicalnetwork.org. The framework will help in the management of specific liver
symptoms.
Many areas around the country are developing electronic palliative care coordination systems (EPACCs) which
should help with the transfer of key information relating to end of life patients and more information can be found
at http://www.endoflifecareforadults.nhs.uk/assets/downloads/EPaCCS_Overview_Road_Shows.pdf
Nottinghamshire Healthcare NHS Trust has a community matron who has developed a case management approach
to high volume service users with addiction issues. This has included care planning for people with advanced liver
disease. www.nottinghamshirehealthcare.nhs.uk
The BASL nurse forum has developed an e-learning resource which includes end of life care and is free to use by all
healthcare professionals and can be accessed at: http://www.basl.org.uk/education-and-training/
King’s College Hospital NHS Foundation Trust has a dedicated palliative care clinical nurse specialist and palliative
care consultant who work as integrated members of the liver team. This has fostered an increased awareness of
palliative and end of life care issues.
County Durham and Darlington Foundation Trust is appointing a palliative care nurse specialist in liver disease to
work in community services.
NHS North East also provide detailed generic guidance on decision triggers, care planning and shared decision
making including the Mental Capacity Act in Deciding Right.
The AMBER care bundle http://www.ambercarebundle.org/homepage.aspx is a tool developed by Guys and St
Thomas’ NHS Trust which provides a systematic approach to manage the care of hospital patients who are facing
an uncertain recovery and who are at risk of dying in the next one to two months. The bundle aims to identify that
recovery is uncertain and therefore aim to make clear decisions regarding a medical plan and discuss preferences
for care with both the patient and carers. It is an intervention that can fit within any care pathway or diagnostic
group for patients whose recovery is uncertain. The AMBER care bundle may be particularly useful for liver patients
in an episode of decompensation when there is potential to benefit from active intervention but recovery remains
uncertain. 
Appendix B: Examples of good practice
Critical care, full
medical intervention, 
responding to
treatment expected
recovery
Recognition of
uncertain recovery
Full intervention with 
added symptom control
Recongition of the
dying phase
Early Planning AMBER Care Bundle Liverpool Care Pathway
Well Uncertain recovery Last days
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